Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon’s Gabitril Marketing Scaled Back Pending Anxiety Trial Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of Gabitril declined 36% to $15.7 mil. in the second quarter.

You may also be interested in...



Gabitril Seizure Warning Addresses Off-Label Use Of High Dose

A new bolded warning for Gabitril (tiagabine) highlighting the risk of non-epileptic seizures is needed because some doctors are using the drug off-label at higher than recommended levels, Cephalon Investor Relations Senior Director Chip Merritt said March 16 at the SG Cowen health care conference in Boston

Cephalon Marketing Practices Under Investigation By Philadelphia U.S. Attorney

Cephalon will turn over documents from 1998 to the present regarding "sales and promotional practices" for Provigil, Gabitril and Actiq.

J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business

The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel